Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Study builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 - NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc.

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD).